Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024
Quantum-Si (Nasdaq: QSI) announced its participation at the Human Proteome Organization (HUPO) World Congress 2024 in Dresden, Germany. The company, known for Next-Generation Protein Sequencing™ (NGPS), will present data from its Platinum® instrument in two poster sessions:
1. Quantum-Si's Next-Generation Protein Sequencer™ for protein detection and peptide characterization from biological samples.
2. Integrated sequencing of single transcript and protein molecules to discern alternatively spliced tropomyosin proteoforms.
Additionally, Quantum-Si will host a breakfast talk on combining NGPS and top-down mass spectrometry for enhanced proteoform analysis. These presentations will showcase Platinum's capabilities in detecting protein variants, post-translational modifications, protein barcoding, and proteoform characterization.
Quantum-Si (Nasdaq: QSI) ha annunciato la sua partecipazione al Congresso Mondiale dell'Organizzazione del Proteoma Umano (HUPO) 2024 a Dresda, Germania. L'azienda, nota per il suo sequenziamento proteico di nuova generazione™ (NGPS), presenterà dati dal suo strumento Platinum® in due sessioni di poster:
1. Sequenziatore proteico di nuova generazione™ di Quantum-Si per la rilevazione delle proteine e la caratterizzazione dei peptidi da campioni biologici.
2. Sequenziamento integrato di singoli trascritti e molecole proteiche per discernere le proteoforme di tropomiosina alternative.
Inoltre, Quantum-Si ospiterà un incontro colazione sulla combinazione di NGPS e spettrometria di massa top-down per un'analisi migliorata delle proteoforme. Queste presentazioni metteranno in mostra le capacità del Platinum nella rilevazione di varianti proteiche, modifiche post-traduzionali, codifica delle proteine e caratterizzazione delle proteoforme.
Quantum-Si (Nasdaq: QSI) anunció su participación en el Congreso Mundial de la Organización del Proteoma Humano (HUPO) 2024 en Dresde, Alemania. La empresa, conocida por su Secuenciación de Proteínas de Nueva Generación™ (NGPS), presentará datos de su instrumento Platinum® en dos sesiones de póster:
1. Secuenciador de proteínas de nueva generación™ de Quantum-Si para la detección de proteínas y caracterización de péptidos a partir de muestras biológicas.
2. Secuenciación integrada de transcritos individuales y moléculas proteicas para discernir las proteoformas de tropomiosina alternadas.
Además, Quantum-Si organizará un desayuno para hablar sobre la combinación de NGPS y espectrometría de masas top-down para una mejor análisis de proteoformas. Estas presentaciones mostrarán las capacidades del Platinum para detectar variantes de proteínas, modificaciones post-traducionales, codificación de proteínas y caracterización de proteoformas.
Quantum-Si (Nasdaq: QSI)는 독일 드레스덴에서 열리는 인간 프로테옴 조직(HUPO) 세계 congress 2024에 참여한다고 발표했습니다. 차세대 단백질 염기서열 분석™(NGPS)으로 알려진 이 회사는 Platinum® 기기에서 얻은 데이터를 두 가지 포스터 세션에서 발표할 예정입니다:
1. 생물학적 샘플에서 단백질 검출 및 펩타이드 특성을 위한 Quantum-Si의 차세대 단백질 염기서열 분석기™.
2. 단일 전사물 및 단백질 분자의 통합 염기서열 분석을 통해 대안적으로 스플라이스된 트로포미오신 프로테오폼을 구별합니다.
추가로 Quantum-Si는 NGPS와 top-down 질량 분석법을 결합한 향상된 프로테오폼 분석을 위한 아침 세미나를 주최할 것입니다. 이러한 발표는 단백질 변종, 번역 후 수식, 단백질 바코딩 및 프로테오폼 특성 분석에서 Platinum의 능력을 보여줄 것입니다.
Quantum-Si (Nasdaq: QSI) a annoncé sa participation au Congrès Mondial de l'Organisation du Protéome Humain (HUPO) 2024 à Dresde, en Allemagne. L'entreprise, connue pour son Séquençage de Protéines de Nouvelle Génération™ (NGPS), présentera des données de son instrument Platinum® lors de deux sessions d'affiches :
1. Séquenceur de protéines de nouvelle génération™ de Quantum-Si pour la détection des protéines et la caractérisation des peptides à partir d'échantillons biologiques.
2. Séquençage intégré de transcrits uniques et de molécules protéiques pour discerner les protéoformes de tropomyosine alternativement épissées.
De plus, Quantum-Si animera un petit-déjeuner-découverte sur la combinaison de NGPS et de la spectrométrie de masse top-down pour une meilleur analyse des protéoformes. Ces présentations mettront en lumière les capacités du Platinum pour détecter les variants de protéines, les modifications post-traductionnelles, le codage des protéines et la caractérisation des protéoformes.
Quantum-Si (Nasdaq: QSI) gab seine Teilnahme am Weltkongress der Human Proteome Organization (HUPO) 2024 in Dresden, Deutschland, bekannt. Das Unternehmen, das für seine Sequenzierung von Proteinen der nächsten Generation™ (NGPS) bekannt ist, wird Daten von seinem Platinum®-Instrument in zwei Postersitzungen präsentieren:
1. Der Next-Generation-Proteinsequencer™ von Quantum-Si zur Proteindetektion und Peptidcharakterisierung aus biologischen Proben.
2. Integrierte Sequenzierung einzelner Transkripte und Proteinmoleküle zur Unterscheidung alternativ gespleißter Tropomyosin-Proteoformen.
Darüber hinaus wird Quantum-Si ein Frühstücksgespräch über die Kombination von NGPS und Top-Down-Massenspektrometrie für eine verbesserte Proteoform-Analyse ausrichten. Diese Präsentationen werden die Fähigkeiten von Platinum bei der Erkennung von Proteinvarianten, post-translationale Modifikationen, Protein-Codierung und Proteoform-Charakterisierung demonstrieren.
- None.
- None.
Quantum-Si’s latest developments, featuring data from Platinum®, the world’s first and only NGPS instrument on the market, will be highlighted in two key poster sessions:
Poster Presentations:
-
Quantum-Si’s Next-Generation Protein Sequencer™ Enables Protein Detection and Peptide Characterization from Biological Samples
- Presented by John Kudolo, PhD, Quantum-Si
- Poster ID: P-III-0753 | Date: Wednesday, October 23
-
Integrated Sequencing of Single Transcript and Protein Molecules Discerns Alternatively Spliced Tropomyosin Proteoforms
-
Presented by Gloria Sheynkman, PhD, University of
Virginia - Poster ID: P-III-0758 | Date: Wednesday, October 23
-
Presented by Gloria Sheynkman, PhD, University of
In addition to the poster presentations, Quantum-Si will host a breakfast talk on Tuesday, October 22, titled “Joining Forces: Next-Generation Protein Sequencing™ and Top-Down Mass Spectrometry Combine to Enhance Proteoform Analysis.” The session will be led by Dr. Meredith Carpenter, Quantum-Si’s Head of Scientific Affairs, and Dr. Neil Kelleher from Northwestern University.
These presentations will showcase new data demonstrating how Platinum addresses applications including detection of protein variants and post-translational modifications, protein barcoding, and characterization of proteoforms in tandem with top-down mass spectrometry.
"We are honored to have such accomplished researchers presenting data from Platinum at HUPO 2024,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si. “The ability to detect and characterize proteins and peptides with such depth and precision is a significant step forward for proteomic research. We continue to believe our technology has the potential to transform how scientists approach biological discovery."
For more information about Quantum-Si’s innovative solutions and to meet the team at World HUPO 2024, attendees can visit booth #24.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010243916/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What events will Quantum-Si (QSI) participate in at HUPO World Congress 2024?
What is Quantum-Si's Platinum® instrument used for?
When and where will Quantum-Si (QSI) present at HUPO World Congress 2024?
What topics will Quantum-Si's (QSI) presentations cover at HUPO 2024?
